Revvity SG&A Expenses 2010-2024 | RVTY

Revvity sg&a expenses for the twelve months ending September 30, 2024 were $1.006B, a 0.37% decline year-over-year.

  • Revvity annual sg&a expenses for 2023 were $1.023B, a 0.29% decline from 2022.
  • Revvity annual sg&a expenses for 2022 were $1.026B, a 5.16% increase from 2021.
  • Revvity annual sg&a expenses for 2021 were $0.975B, a 36.11% increase from 2020.

Revvity SG&A Expenses 2010-2024 | RVTY

  • Revvity annual sg&a expenses for 2023 were $1.023B, a 0.29% decline from 2022.
  • Revvity annual sg&a expenses for 2022 were $1.026B, a 5.16% increase from 2021.
  • Revvity annual sg&a expenses for 2021 were $0.975B, a 36.11% increase from 2020.
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$93.4B
Cencora (COR)$48.3B
DiDi Global (DIDIY)$22.2B
Natera (NTRA)$22.1B
ICON (ICLR)$17.7B
Viatris (VTRS)$16B
Avantor (AVTR)$14.1B
CochLear (CHEOY)$12.8B
Solventum (SOLV)$12.2B
BioMerieux (BMXMF)$11.9B
Medpace Holdings (MEDP)$10.5B
Charles River Laboratories (CRL)$10B
HealthEquity (HQY)$9.1B
Doximity (DOCS)$9B
Sonic Healthcare (SKHHY)$8.9B
Bausch + Lomb (BLCO)$6.9B
Life Times (LTH)$5.1B
Organon (OGN)$3.9B
Sotera Health (SHC)$3.6B
BrightSpring Health Services (BTSG)$3.3B
Surgery Partners (SGRY)$2.9B
Concentras Parent (CON)$2.8B
PACS (PACS)$2.5B
Alignment Healthcare (ALHC)$2.3B
Ardent Health Partners (ARDT)$2.3B
Premier (PINC)$2.2B
GeneDx Holdings (WGS)$2.2B
Ryman Healthcare (RYHTY)$2B
GoodRx Holdings (GDRX)$1.9B
Teladoc Health (TDOC)$1.8B